A Phase 2 interventional study of REGN5381 and Matching Placebo in Heart Failure, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Moldova. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication for right heart catheterization (RHC). The aim of the study is to evaluate the safety and tolerability of the study drug.
The study is looking at several other research questions, including:
Note: Group A has stopped enrolling and Group B will not enroll participants
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
This study's enrollment of 59 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized 1:1; limited to participants with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan
Drug: REGN5381 · Drug: Matching Placebo
Randomized 1:1; limited to participants with HFrEF taking sacubitril/valsartan
Drug: REGN5381 · Drug: Matching Placebo
Randomized 1:1; limited to participants with heart failure with preserved ejection fraction (HFpEF) not taking sacubitril/valsartan
Drug: REGN5381 · Drug: Matching Placebo
Single dose administered via IV infusion
Single dose administered via IV infusion
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as those adverse events with either initial onset after study drug dose or that represented an exacerbation of a pre-existing condition after the study drug dose.
Time frame: From first dose (Day 1) up to end of study (Day 126)
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP)
PCWP was collected during the right heart catheterization on Day 1.
Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
Change From Baseline in Central Venous Pressure (CVP)
CVP was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CVP was not captured.
Time frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Change From Baseline in Invasive Cardiac Output (CO)
CO was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CO was not captured.
Time frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Change From Baseline in Systemic Vascular Resistance (SVR)
SVR was derived as follows: \[(Mean Arterial Pressure-Central Venous Pressure)\*80\]/ Invasive Cardiac Output. For the Group A: 10 mg cohort, the site's bedside monitor was not compatible with the invasive hemodynamic measurement device. As a result, CVP was not captured, and SVR could not be calculated due to the missing CVP data.
Time frame: Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)
mPAP was collected during the right heart catheterization on day 1.
Time frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
Change From Baseline in Pulmonary Vascular Resistance (PVR)
Pulmonary Vascular Resistance was derived as follows: \[(Mean Pulmonary Artery Pressure-Pulmonary Capillary Wedge Pressure)\*80\]/ Invasive Cardiac Output.
Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
Change From Baseline in Systolic Blood Pressure (SBP)
For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing right heart catheterization (RHC).
Time frame: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Change From Baseline in Diastolic Blood Pressure (DBP)
For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.
Time frame: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Change From Baseline in Mean Arterial Pressure (MAP)
MAP was derived as follows: (1/3\*SBP + 2/3\*DBP).
Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Change From Baseline in Pulse Rate (PR)
For participants enrolled in Group A cohorts, pulse rate was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.
Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Fold Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-Baseline to Baseline, and it is assumed to follow a lognormal distribution. Per the study design, only some participants had a Day 4/Day 5 visit. Therefore, NT-proBNP data were not collected at this time point for all participants.
Time frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
Peak Concentration (Cmax) of REGN5381 in Serum
Time frame: Up to Day 126
Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum
Time frame: Up to Day 126
Number of Participants With Anti-drug Antibodies (ADA)
The ADA status of each participant was classified as one of the following: * Negative - If all samples were found to be negative in the ADA assay * Pre-existing immunoreactivity - If the baseline sample was positive and all post baseline ADA titers were reported as less than 9-fold the baseline titer value * Treatment-Boosted Response * Treatment-Emergent Response
Time frame: Baseline up to Day 126
| Milestone | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 3 | 3 | 6 | 4 | 18 | 3 | 3 | 12 |
| Received study treatment | 7 | 3 | 3 | 6 | 4 | 18 | 3 | 3 | 12 |
| Completed | 7 | 3 | 3 | 6 | 3 | 18 | 3 | 3 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as those adverse events with either initial onset after study drug dose or that represented an exacerbation of a pre-existing condition after the study drug dose.
| Participants | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 4 |
PCWP was collected during the right heart catheterization on Day 1.
| millimeters of mercury (mmHg) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| 2 hours post end of infusion | -4.7 ± 3.34 | -5.9 ± 6.00 | -4.6 ± 1.67 | -7.1 ± 3.12 | -5.8 ± 3.80 | -2.7 ± 1.66 | -5.9 ± 5.67 | -7.6 ± 1.50 | -4.8 ± 1.51 |
| 4 hours post end of infusion | -5.4 ± 2.49 | -4.7 ± 6.24 | -4.7 ± 2.91 | -6.3 ± 2.09 | -7.4 ± 4.56 | -3.2 ± 1.95 | -5.8 ± 4.88 | -7.0 ± 0.88 | -5.4 ± 2.14 |
| 6 hours post end of infusion | -3.8 ± 2.67 | -4.6 ± 5.48 | -3.3 ± 3.93 | -8.0 ± 1.59 | -6.7 ± 6.65 | -3.3 ± 2.32 | -4.8 ± 4.17 | -9.3 ± 1.41 | -7.2 ± 2.22 |
CVP was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CVP was not captured.
| mmHg | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| 0-1 hour post start of infusion | 1.7 ± 1.62 | — | -4.6 ± 7.71 | -0.2 ± 0.43 | -0.3 ± 0.44 | -0.3 ± 1.56 | -0.3 ± 1.82 | -0.2 ± 0.15 | -0.6 ± 2.52 |
| 1-2 hours post start of infusion | 1.2 ± 2.07 | — | -4.1 ± 7.96 | 0.0 ± 1.08 | -1.6 ± 1.09 | -0.9 ± 2.04 | -1.1 ± 2.58 | -1.7 ± 1.18 | -1.6 ± 2.64 |
| 2-3 hours post start of infusion | -0.7 ± 3.73 | — | -6.0 ± 8.37 | -0.3 ± 3.26 | -2.9 ± 1.97 | -1.8 ± 1.44 | -1.3 ± 1.41 | -2.1 ± 1.15 | -1.7 ± 2.35 |
| 3-4 hours post start of infusion | -0.3 ± 2.76 | — | -5.5 ± 7.95 | -1.3 ± 1.03 | -2.8 ± 1.98 | -1.4 ± 2.78 | -3.2 ± 2.15 | -2.3 ± 2.13 | -3.3 ± 2.79 |
| 4-5 hours post start of infusion | -0.5 ± 3.39 | — | -6.7 ± 8.67 | -1.5 ± 1.40 | -4.1 ± 3.26 | -2.2 ± 2.54 | -4.1 ± 2.80 | -2.9 ± 1.84 | -4.3 ± 2.29 |
| 5-6 hours post start of infusion | -0.7 ± 1.95 | — | -5.7 ± 8.61 | -2.3 ± 1.57 | -4.7 ± 3.80 | -2.7 ± 2.73 | -3.5 ± 1.24 | -3.6 ± 1.52 | -4.4 ± 2.39 |
| 6-7 hours post start of infusion | 0.2 ± 2.23 | — | -5.6 ± 8.92 | -3.2 ± 2.42 | -4.6 ± 3.07 | -3.0 ± 2.48 | -4.1 ± 2.32 | -3.3 ± 0.55 | -5.0 ± 2.82 |
CO was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CO was not captured.
| Liters per minute (L/min) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| 0-1 hour post start of infusion | 0.16 ± 0.953 | — | -0.44 ± 1.258 | 0.17 ± 0.674 | 0.27 ± 0.157 | -0.14 ± 0.547 | -0.01 ± 0.394 | 0.12 ± 0.260 | -0.36 ± 0.598 |
| 1-2 hours post start of infusion | 0.29 ± 0.811 | — | -0.57 ± 1.555 | 0.03 ± 0.942 | 0.48 ± 0.829 | 0.05 ± 0.622 | 0.02 ± 0.552 | 0.26 ± 0.255 | -0.37 ± 0.658 |
| 2-3 hours post start of infusion | 0.00 ± 1.005 | — | -0.64 ± 1.337 | -0.08 ± 0.894 | 0.31 ± 0.866 | 0.25 ± 0.404 | 0.39 ± 0.713 | 0.09 ± 0.381 | -0.23 ± 0.849 |
| 3-4 hours post start of infusion | 0.39 ± 0.705 | — | -0.91 ± 1.409 | -0.53 ± 0.946 | 0.36 ± 1.111 | 0.46 ± 0.807 | 0.84 ± 0.846 | 0.21 ± 0.386 | -0.08 ± 1.020 |
| 4-5 hours post start of infusion | 0.61 ± 1.120 | — | -1.31 ± 0.444 | -0.12 ± 1.214 | 0.48 ± 1.271 | 0.75 ± 0.856 | 0.00 ± 1.257 | 0.12 ± 0.482 | -0.39 ± 1.055 |
| 5-6 hours post start of infusion | 0.18 ± 1.128 | — | -1.06 ± 0.912 | 0.27 ± 1.550 | 0.18 ± 0.926 | 0.55 ± 0.663 | -0.40 ± 0.993 | 0.01 ± 0.339 | -0.31 ± 0.970 |
| 6-7 hours post start of infusion | 0.06 ± 1.186 | — | -1.22 ± 0.530 | 0.06 ± 1.140 | -0.01 ± 1.182 | 0.42 ± 0.788 | 0.14 ± 0.914 | -0.45 ± 0.575 | -0.63 ± 1.173 |
SVR was derived as follows: \[(Mean Arterial Pressure-Central Venous Pressure)\*80\]/ Invasive Cardiac Output. For the Group A: 10 mg cohort, the site's bedside monitor was not compatible with the invasive hemodynamic measurement device. As a result, CVP was not captured, and SVR could not be calculated due to the missing CVP data.
| dynes*second/centimeter^5 (dynes*s/cm^5) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| 0 hours post end of infusion | -532.3 | — | — | — | -140.4 ± 376.06 | -47.0 ± 249.47 | 8.8 ± 341.15 | -134.2 ± 37.16 | 110.1 ± 350.02 |
| 1 hour post end of infusion | -177.8 ± 57.33 | — | — | — | -135.8 ± 621.85 | 22.8 ± 281.92 | -111.9 ± 349.44 | -98.8 ± 42.21 | 195.3 ± 316.23 |
| 2 hours post end of infusion | -200.2 ± 393.80 | — | 144.4 ± 410.20 | -111.1 ± 161.60 | 72.2 ± 530.78 | -48.4 ± 248.87 | -417.6 ± 436.76 | -87.6 ± 130.03 | -31.1 ± 266.34 |
| 3 hours post end of infusion | -783.1 | — | — | — | -8.1 ± 369.55 | -187.5 ± 320.75 | -279.4 ± 584.68 | -176.0 ± 157.69 | 22.2 ± 380.63 |
| 4 hours post end of infusion | -286.9 ± 426.15 | — | 337.1 ± 212.36 | -92.5 ± 343.89 | 67.0 ± 499.98 | -204.9 ± 303.79 | 315.9 ± 432.37 | -175.3 ± 233.77 | 166.1 ± 348.38 |
| 5 hours post end of infusion | -931.1 | — | — | — | 56.9 ± 199.05 | -74.1 ± 263.81 | -44.3 ± 323.25 | -89.4 ± 270.01 | 103.2 ± 316.66 |
| 6 hours post end of infusion | -26.1 ± 514.13 | — | 207.5 ± 35.47 | -273.2 ± 399.00 | 243.2 ± 583.73 | -58.5 ± 262.84 | -53.2 ± 211.54 | -26.3 ± 234.13 | 196.8 ± 369.07 |
mPAP was collected during the right heart catheterization on day 1.
| mmHg | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| 0-1 hour post start of infusion | 0.5 ± 1.39 | -0.3 ± 5.15 | 0.3 ± 0.84 | -2.2 ± 2.52 | -0.2 ± 1.52 | 0.2 ± 1.46 | -1.4 ± 2.78 | -0.8 ± 0.04 | -0.8 ± 1.50 |
| 1-2 hours post start of infusion | 1.1 ± 2.05 | 4.2 ± 0.92 | 0.6 ± 1.70 | -2.1 ± 2.09 | -1.7 ± 2.48 | 0.2 ± 2.05 | -1.9 ± 2.13 | -2.9 ± 2.04 | -1.0 ± 1.89 |
| 2-3 hours post start of infusion | -1.6 ± 1.62 | 0.4 ± 4.16 | -4.0 ± 4.61 | -2.3 ± 1.76 | -2.3 ± 1.57 | -0.4 ± 1.61 | -2.1 ± 3.94 | -3.6 ± 3.17 | -1.8 ± 2.08 |
| 3-4 hours post start of infusion | -1.4 ± 0.90 | -4.1 ± 1.27 | -1.4 ± 1.82 | -4.5 ± 1.58 | -2.9 ± 1.49 | -0.2 ± 2.56 | -4.3 ± 5.98 | -5.8 ± 4.69 | -2.9 ± 2.95 |
| 4-5 hours post start of infusion | -1.6 ± 2.40 | -2.1 ± 3.05 | -7.2 ± 9.51 | -2.4 ± 4.13 | -3.9 ± 3.89 | -1.6 ± 1.56 | -6.0 ± 5.73 | -6.4 ± 3.42 | -4.2 ± 2.10 |
| 5-6 hours post start of infusion | -1.9 ± 1.55 | -0.8 ± 2.33 | -3.0 ± 4.22 | -5.5 ± 2.08 | -4.6 ± 5.69 | -2.3 ± 2.45 | -5.0 ± 4.53 | -7.6 ± 6.64 | -4.6 ± 1.80 |
| 6-7 hours post start of infusion | -0.4 ± 1.33 | -0.1 ± 2.66 | -4.6 ± 8.28 | -5.5 ± 3.15 | -4.5 ± 4.40 | -2.2 ± 2.38 | -5.7 ± 6.79 | -3.8 ± 1.45 | -5.2 ± 2.95 |
Pulmonary Vascular Resistance was derived as follows: \[(Mean Pulmonary Artery Pressure-Pulmonary Capillary Wedge Pressure)\*80\]/ Invasive Cardiac Output.
| dynes*s/cm^5 | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| 2 hours post end of infusion | 11.5 ± 45.44 | — | 72.1 ± 55.44 | 78.2 ± 37.28 | 89.9 ± 96.89 | 31.5 ± 52.14 | 13.5 ± 13.55 | 30.0 ± 68.26 | 59.1 ± 82.64 |
| 4 hours post end of infusion | 15.3 ± 74.84 | — | 84.8 ± 53.05 | 64.1 ± 74.11 | 114.4 ± 172.35 | -2.1 ± 49.65 | 69.1 ± 42.29 | 7.5 ± 66.87 | 37.6 ± 46.72 |
| 6 hours post end of infusion | 7.7 ± 95.34 | — | 37.7 ± 38.82 | 55.2 ± 70.42 | 147.8 ± 164.45 | -1.1 ± 51.76 | -21.4 ± 73.65 | 51.2 ± 35.76 | 68.6 ± 76.60 |
For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing right heart catheterization (RHC).
| mmHg | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 (0 hours post end of infusion) | 3.7 ± 11.59 | — | — | 2.0 ± 8.49 | 1.5 ± 5.57 | -0.8 ± 8.83 | 1.7 ± 13.61 | -1.7 ± 4.51 | 1.6 ± 9.22 |
| Day 1 (1 hour post end of infusion) | 4.0 ± 5.29 | — | — | 3.0 ± 1.41 | 3.8 ± 9.00 | -0.5 ± 10.89 | -1.7 ± 13.65 | -4.3 ± 5.77 | -0.6 ± 12.70 |
| Day 1 (2 hours post end of infusion) | 3.0 ± 11.02 | -10.3 ± 12.01 | -7.7 ± 5.51 | -7.5 ± 5.32 | 1.3 ± 8.50 | -0.6 ± 10.31 | -13.0 ± 11.79 | -5.0 ± 6.56 | -6.7 ± 14.00 |
| Day 1 (3 hours post end of infusion) | -5.0 ± 3.46 | — | — | -5.5 ± 6.36 | 2.5 ± 8.50 | -4.7 ± 8.92 | -12.7 ± 10.50 | -12.7 ± 4.16 | -8.3 ± 16.09 |
| Day 1 (4 hours post end of infusion) | -2.3 ± 4.03 | -9.0 ± 9.64 | -9.0 ± 13.45 | -2.3 ± 7.66 | -0.5 ± 8.35 | -4.6 ± 10.59 | 2.7 ± 2.31 | -10.3 ± 9.24 | -7.5 ± 13.91 |
| Day 1 (5 hours post end of infusion) | 3.0 ± 12.17 | — | — | -4.0 ± 8.49 | -6.5 ± 16.42 | -1.9 ± 10.75 | -7.7 ± 15.01 | -6.3 ± 14.05 | -7.7 ± 13.98 |
| Day 1 (6 hours post end of infusion) | -1.3 ± 2.56 | -7.3 ± 15.04 | -2.0 ± 6.93 | -5.7 ± 7.26 | -7.5 ± 15.61 | -1.5 ± 11.52 | -1.7 ± 10.69 | -5.7 ± 6.43 | -7.9 ± 13.21 |
| Day 2 (first 8 hours) | -6.7 ± 16.33 | -13.3 ± 2.08 | 7.0 ± 20.66 | -7.2 ± 9.75 | -8.5 ± 21.19 | -12.9 ± 15.22 | -14.7 ± 15.53 | -8.0 ± 6.93 | -15.2 ± 14.55 |
| Day 2 (second 8 hours) | -20.7 ± 15.40 | -17.7 ± 8.62 | -7.0 ± 18.33 | -11.0 ± 11.78 | -8.3 ± 25.05 | -21.8 ± 14.63 | -15.7 ± 14.05 | -7.3 ± 5.03 | -22.3 ± 8.52 |
| Day 2 (third 8 hours) | -10.9 ± 11.81 | -21.7 ± 11.37 | -4.0 ± 24.27 | -9.2 ± 11.36 | -7.5 ± 16.84 | -13.4 ± 15.27 | -14.7 ± 9.81 | -14.3 ± 11.24 | -11.8 ± 11.09 |
| Day 3 (first 8 hours) | -16.1 ± 16.75 | -18.0 ± 6.24 | -8.7 ± 9.50 | -4.8 ± 10.01 | -7.5 ± 13.23 | -20.4 ± 14.21 | -22.3 ± 16.29 | -18.3 ± 11.55 | -11.3 ± 11.24 |
| Day 3 (second 8 hours) | -11.0 ± 7.26 | — | — | -3.3 ± 9.29 | — | -15.8 ± 16.88 | -12.0 ± 13.23 | -8.7 ± 7.37 | -19.7 ± 13.45 |
| Day 3 (third 8 hours) | -6.8 ± 21.25 | — | — | -5.3 ± 11.06 | — | -12.1 ± 15.69 | -6.7 ± 16.04 | -6.0 ± 3.46 | -5.6 ± 17.47 |
| Day 4 (first 8 hours) | -7.8 ± 14.31 | — | — | -2.0 ± 17.58 | -39.0 | -18.9 ± 15.94 | -15.7 ± 15.57 | -12.3 ± 2.08 | -8.5 ± 13.85 |
| Day 4 (second 8 hours) | 2.0 | — | — | 0.0 ± 8.49 | — | -16.3 ± 19.67 | -9.3 ± 18.23 | -17.5 ± 2.12 | -9.7 ± 12.49 |
| Day 4 (third 8 hours) | -9.0 | — | — | -4.5 ± 10.61 | — | -12.7 ± 16.84 | -9.3 ± 13.65 | -15.0 ± 5.66 | -9.1 ± 9.17 |
| Day 5 (first 8 hours) | -8.0 | — | — | 0.0 ± 21.21 | — | -16.6 ± 16.98 | -22.3 ± 22.37 | -20.0 ± 13.00 | -10.0 ± 11.10 |
| Day 5 (second 8 hours) | — | — | — | -7.0 | — | -6.5 ± 19.09 | — | — | -17.0 ± 12.73 |
| Day 5 (third 8 hours) | — | — | — | -2.0 | — | -13.0 ± 18.38 | — | — | -5.0 ± 9.90 |
| Day 6 (first 8 hours) | — | — | — | -6.0 | — | — | — | — | — |
| Day 8 | -4.1 ± 15.23 | -12.0 ± 13.75 | 8.3 ± 4.51 | 2.8 ± 12.73 | -13.3 ± 19.86 | -16.6 ± 17.39 | -21.7 ± 8.74 | -16.3 ± 6.43 | -3.9 ± 12.71 |
| Day 15 | -7.3 ± 10.48 | -8.7 ± 17.47 | 9.3 ± 6.66 | -4.8 ± 9.99 | -8.0 ± 14.11 | -9.7 ± 15.86 | -15.7 ± 13.01 | -12.7 ± 6.81 | -3.8 ± 10.94 |
| Day 22 | -9.1 ± 12.08 | -15.7 ± 17.90 | 4.3 ± 7.09 | 1.3 ± 16.02 | 0.3 ± 26.39 | -8.8 ± 16.37 | -9.0 ± 14.11 | -17.7 ± 10.97 | 0.0 ± 12.95 |
| Day 36 | -14.5 ± 13.84 | — | 2.3 ± 11.93 | 1.5 ± 13.77 | -1.0 ± 24.76 | -12.4 ± 13.88 | -7.3 ± 13.20 | -11.3 ± 9.29 | -4.1 ± 12.84 |
| Day 57 | -4.2 ± 8.98 | — | — | 1.8 ± 17.79 | -3.7 ± 25.38 | -10.4 ± 11.83 | — | -14.0 ± 11.53 | -1.4 ± 13.69 |
| Day 78 | -9.8 ± 11.90 | — | — | -0.5 ± 15.50 | -10.7 ± 17.56 | -9.5 ± 12.28 | — | -18.7 ± 7.64 | -3.5 ± 8.95 |
| Day 99 | -4.0 ± 14.14 | — | — | — | -13.7 ± 29.70 | -4.0 ± 13.21 | — | — | -4.3 ± 16.69 |
| Day 126 | -8.0 ± 15.56 | — | — | — | -1.7 ± 10.60 | -9.8 ± 16.01 | — | — | -6.0 ± 14.53 |
For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.
| mmHg | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 (0 hours post end of infusion) | 0.3 ± 8.08 | — | — | 6.0 ± 5.66 | -3.3 ± 5.62 | -1.0 ± 5.78 | 0.0 ± 5.20 | -2.7 ± 4.51 | 0.7 ± 6.80 |
| Day 1 (1 hour post end of infusion) | 1.7 ± 2.89 | — | — | 4.0 ± 2.83 | -1.8 ± 6.50 | 0.8 ± 8.14 | -1.3 ± 2.31 | -4.7 ± 4.73 | 0.8 ± 4.73 |
| Day 1 (2 hours post end of infusion) | 0.9 ± 7.90 | -3.3 ± 6.03 | -7.7 ± 4.51 | -8.3 ± 5.28 | -0.5 ± 5.45 | -0.8 ± 7.96 | -9.3 ± 10.50 | -7.3 ± 6.66 | -1.2 ± 8.08 |
| Day 1 (3 hours post end of infusion) | -4.7 ± 5.69 | — | — | -4.0 ± 8.49 | -1.3 ± 6.85 | -3.1 ± 6.77 | -6.3 ± 9.61 | -8.3 ± 1.53 | -3.8 ± 8.94 |
| Day 1 (4 hours post end of infusion) | -3.9 ± 5.21 | -8.3 ± 5.77 | -8.0 ± 11.36 | -2.3 ± 6.56 | -3.0 ± 4.69 | -2.7 ± 7.69 | 0.0 ± 4.00 | -7.3 ± 4.04 | -4.4 ± 8.20 |
| Day 1 (5 hours post end of infusion) | 0.0 ± 5.00 | — | — | -2.0 ± 4.24 | -4.3 ± 6.80 | -0.6 ± 7.24 | 0.0 ± 8.54 | -5.7 ± 7.02 | -4.1 ± 9.17 |
| Day 1 (6 hours post end of infusion) | -1.3 ± 6.32 | -7.7 ± 7.51 | -6.7 ± 13.43 | -4.8 ± 7.70 | -5.8 ± 6.50 | 1.9 ± 9.10 | 1.3 ± 2.89 | -6.7 ± 4.73 | -3.3 ± 8.15 |
| Day 2 (first 8 hours) | -7.3 ± 7.99 | -10.7 ± 1.53 | -0.3 ± 13.58 | -8.2 ± 6.82 | -12.8 ± 12.58 | -7.2 ± 9.85 | -9.0 ± 9.00 | -3.3 ± 3.21 | -9.1 ± 8.02 |
| Day 2 (second 8 hours) | -15.3 ± 7.52 | -18.3 ± 6.35 | -9.0 ± 13.08 | -10.7 ± 7.94 | -13.3 ± 10.84 | -10.3 ± 10.03 | -9.7 ± 5.51 | -5.7 ± 7.02 | -13.6 ± 8.62 |
| Day 2 (third 8 hours) | -9.7 ± 10.89 | -16.3 ± 7.77 | -9.0 ± 16.82 | -8.7 ± 10.27 | -8.5 ± 8.50 | -9.3 ± 9.87 | -11.0 ± 8.19 | -8.0 ± 6.24 | -8.2 ± 7.47 |
| Day 3 (first 8 hours) | -11.9 ± 11.98 | -13.7 ± 6.11 | -13.0 ± 8.54 | -8.5 ± 4.72 | -9.8 ± 6.24 | -11.3 ± 8.78 | -15.0 ± 15.10 | -8.7 ± 5.03 | -5.7 ± 7.40 |
| Day 3 (second 8 hours) | -8.3 ± 6.34 | — | — | -5.3 ± 7.51 | — | -8.6 ± 11.12 | -14.3 ± 9.07 | -6.7 ± 4.93 | -10.9 ± 8.77 |
| Day 3 (third 8 hours) | -5.3 ± 12.97 | — | — | -4.3 ± 11.02 | — | -7.1 ± 8.37 | -16.3 ± 14.22 | -5.3 ± 3.06 | -5.2 ± 11.61 |
| Day 4 (first 8 hours) | -6.3 ± 12.53 | — | — | -6.3 ± 15.63 | -31.0 | -8.8 ± 9.01 | -14.7 ± 4.62 | -8.3 ± 4.04 | -6.5 ± 8.15 |
| Day 4 (second 8 hours) | -3.0 | — | — | -1.0 ± 5.66 | — | -8.2 ± 12.28 | -15.3 ± 14.64 | -12.0 ± 8.49 | -6.8 ± 7.29 |
| Day 4 (third 8 hours) | -15.0 | — | — | -4.5 ± 9.19 | — | -6.4 ± 11.54 | -15.7 ± 9.24 | -8.0 ± 5.66 | -7.2 ± 6.94 |
| Day 5 (first 8 hours) | 2.0 | — | — | -0.5 ± 19.09 | — | -8.1 ± 10.10 | -16.0 ± 15.13 | -11.7 ± 7.51 | -8.2 ± 7.93 |
| Day 5 (second 8 hours) | — | — | — | -8.0 | — | -6.5 ± 12.02 | — | — | -11.5 ± 3.54 |
| Day 5 (third 8 hours) | — | — | — | 0.0 | — | -9.0 ± 8.49 | — | — | -7.0 ± 2.83 |
| Day 6 (first 8 hours) | — | — | — | -8.0 | — | — | — | — | — |
| Day 8 | -5.6 ± 13.25 | -7.0 ± 15.72 | -4.3 ± 2.89 | -2.7 ± 8.80 | -12.7 ± 13.87 | -9.3 ± 10.46 | -15.7 ± 11.93 | -9.3 ± 3.51 | -2.8 ± 7.03 |
| Day 15 | -7.7 ± 5.68 | -6.3 ± 13.65 | -1.3 ± 3.06 | -5.5 ± 11.15 | -12.7 ± 6.51 | -5.2 ± 8.77 | -10.0 ± 9.64 | -7.0 ± 6.00 | -4.8 ± 5.47 |
| Day 22 | -8.0 ± 7.26 | -16.3 ± 9.50 | -2.0 ± 5.29 | -2.7 ± 7.12 | -10.7 ± 16.62 | -3.1 ± 9.29 | -12.0 ± 9.54 | -9.7 ± 3.06 | -3.8 ± 7.59 |
| Day 36 | -12.3 ± 8.85 | — | -6.7 ± 12.42 | -1.5 ± 14.29 | -15.7 ± 20.74 | -5.3 ± 6.82 | -10.7 ± 7.37 | -6.7 ± 5.86 | -5.1 ± 12.91 |
| Day 57 | -5.8 ± 7.36 | — | — | -2.5 ± 15.88 | -17.0 ± 22.61 | -4.5 ± 7.02 | — | -6.3 ± 6.43 | -2.7 ± 5.63 |
| Day 78 | -5.6 ± 5.77 | — | — | -6.5 ± 14.24 | -16.0 ± 13.89 | -3.3 ± 6.69 | — | -8.3 ± 3.06 | -5.8 ± 6.94 |
| Day 99 | -2.0 ± 2.83 | — | — | — | -18.0 ± 18.25 | -0.3 ± 6.20 | — | — | -3.8 ± 8.50 |
| Day 126 | -6.0 ± 12.73 | — | — | — | -11.7 ± 14.01 | -3.8 ± 10.82 | — | — | -4.2 ± 10.79 |
MAP was derived as follows: (1/3\*SBP + 2/3\*DBP).
| mmHg | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 (2 hours post end of infusion) | 1.5 ± 9.10 | -5.6 ± 7.13 | -7.3 ± 2.91 | -8.4 ± 5.03 | 0.0 ± 2.33 | -0.5 ± 8.64 | -9.4 ± 11.75 | -7.8 ± 4.81 | -3.4 ± 8.69 |
| Day 1 (4 hours post end of infusion) | -3.4 ± 4.30 | -8.8 ± 4.17 | -8.1 ± 12.08 | -2.7 ± 6.84 | -1.9 ± 0.96 | -3.3 ± 8.27 | 2.2 ± 2.34 | -8.3 ± 5.70 | -5.4 ± 8.87 |
| Day 1 (6 hours post end of infusion) | -1.0 ± 5.04 | -7.7 ± 11.02 | -5.0 ± 11.67 | -5.6 ± 7.96 | -7.2 ± 7.83 | 0.8 ± 9.75 | 1.6 ± 5.48 | -6.7 ± 4.41 | -5.1 ± 9.01 |
| Day 2 (first 8 hours) | -7.4 ± 10.44 | -12.3 ± 1.20 | 1.9 ± 15.60 | -8.3 ± 6.80 | -11.6 ± 14.23 | -8.9 ± 10.93 | -10.2 ± 10.03 | -5.4 ± 3.83 | -11.7 ± 9.31 |
| Day 2 (second 8 hours) | -17.0 ± 8.84 | -18.8 ± 7.24 | -8.2 ± 15.00 | -10.8 ± 8.72 | -10.8 ± 16.01 | -14.1 ± 9.68 | -11.4 ± 8.50 | -6.9 ± 5.83 | -16.8 ± 8.04 |
| Day 2 (third 8 hours) | -10.2 ± 10.90 | -18.1 ± 7.43 | -7.7 ± 19.22 | -8.7 ± 10.39 | -7.2 ± 10.93 | -10.5 ± 10.10 | -10.3 ± 8.41 | -10.1 ± 7.90 | -9.8 ± 8.33 |
| Day 3 (first 8 hours) | -13.0 ± 12.70 | -15.6 ± 4.17 | -11.7 ± 7.62 | -8.1 ± 5.98 | 9.2 ± 8.57 | -14.0 ± 8.91 | -16.9 ± 14.54 | -12.2 ± 6.99 | -7.7 ± 7.66 |
| Day 3 (second 8 hours) | -9.6 ± 6.56 | — | — | -5.1 ± 6.47 | — | -10.6 ± 12.17 | -12.3 ± 8.19 | -7.6 ± 5.54 | -13.9 ± 9.23 |
| Day 3 (third 8 hours) | -5.6 ± 15.57 | — | — | -4.3 ± 10.49 | — | -8.8 ± 9.95 | -12.2 ± 13.49 | -5.8 ± 3.27 | -4.6 ± 13.09 |
| Day 8 | -4.3 ± 12.43 | -9.1 ± 14.83 | -0.2 ± 3.56 | -0.9 ± 10.06 | -12.9 ± 14.00 | -11.5 ± 12.01 | -16.9 ± 9.73 | -12.0 ± 4.26 | -2.4 ± 7.82 |
| Day 15 | -7.4 ± 7.15 | -8.0 ± 14.71 | 1.9 ± 3.91 | -4.9 ± 10.56 | -11.2 ± 7.38 | -6.2 ± 10.02 | -12.9 ± 8.66 | -9.2 ± 6.74 | -4.2 ± 5.43 |
| Day 22 | -8.1 ± 7.78 | -17.3 ± 10.68 | 0.2 ± 5.82 | -1.4 ± 10.23 | -7.0 ± 19.01 | -5.2 ± 10.63 | -8.7 ± 9.17 | -12.7 ± 5.46 | -2.9 ± 7.51 |
| Day 36 | -13.6 ± 9.41 | — | -3.6 ± 12.73 | -1.1 ± 12.99 | -11.7 ± 21.23 | -7.5 ± 7.78 | -8.6 ± 7.58 | -8.0 ± 7.06 | -5.2 ± 12.01 |
| Day 57 | -4.7 ± 3.89 | — | — | -1.4 ± 16.42 | -12.3 ± 23.69 | -6.5 ± 7.86 | — | -9.4 ± 7.90 | -2.0 ± 6.75 |
| Day 78 | -6.7 ± 6.97 | — | — | -3.9 ± 13.83 | -14.0 ± 15.77 | -5.7 ± 7.66 | — | -11.3 ± 2.03 | -5.1 ± 6.94 |
| Day 99 | -3.0 ± 2.36 | — | — | — | -17.1 ± 21.27 | -1.9 ± 7.61 | — | — | -3.9 ± 10.42 |
| Day 126 | -5.7 ± 4.71 | — | — | — | -8.7 ± 12.00 | -5.9 ± 11.81 | — | — | -4.6 ± 11.30 |
For participants enrolled in Group A cohorts, pulse rate was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC.
| beats per minute (bpm) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 (2 hours post end of infusion) | 1.3 ± 5.85 | -5.3 ± 7.57 | 7.7 ± 8.33 | -3.5 ± 6.38 | 11.8 ± 9.64 | 2.4 ± 5.09 | 8.0 ± 13.89 | 3.7 ± 0.58 | 6.5 ± 16.19 |
| Day 1 (4 hours post end of infusion) | -5.4 ± 6.00 | -1.3 ± 4.93 | 4.7 ± 2.89 | -0.7 ± 4.46 | 7.5 ± 8.81 | 2.7 ± 6.50 | 0.0 ± 5.57 | 4.7 ± 4.04 | 5.0 ± 9.94 |
| Day 1 (6 hours post end of infusion) | -1.7 ± 5.31 | -3.0 ± 8.19 | 4.3 ± 1.15 | -2.0 ± 3.85 | 16.5 ± 10.28 | 2.9 ± 5.63 | 9.0 ± 14.73 | 5.3 ± 6.66 | 4.3 ± 9.24 |
| Day 2 (first 8 hours) | -4.4 ± 10.03 | -5.3 ± 11.02 | 11.7 ± 6.66 | -4.5 ± 7.12 | 17.0 ± 20.12 | 4.2 ± 9.80 | 1.3 ± 3.51 | 4.7 ± 6.51 | 1.4 ± 11.22 |
| Day 2 (second 8 hours) | -2.3 ± 13.57 | -11.0 ± 1.00 | 6.3 ± 4.93 | -2.2 ± 6.37 | 6.8 ± 25.55 | 4.1 ± 7.09 | -0.3 ± 3.51 | 3.3 ± 5.51 | 4.5 ± 8.17 |
| Day 2 (third 8 hours) | -0.9 ± 17.33 | -8.3 ± 4.51 | 4.0 ± 6.08 | -4.2 ± 5.56 | 9.3 ± 22.23 | 1.8 ± 6.39 | -1.3 ± 4.16 | 1.7 ± 7.51 | 1.3 ± 9.06 |
| Day 3 (first 8 hours) | 0.9 ± 14.65 | -7.0 ± 10.44 | 1.0 ± 3.61 | -5.0 ± 7.32 | 2.3 ± 18.25 | 1.1 ± 8.05 | -1.3 ± 10.21 | 2.3 ± 8.74 | -1.7 ± 9.61 |
| Day 3 (second 8 hours) | 10.5 ± 10.28 | — | — | 2.0 ± 8.19 | — | 1.9 ± 5.99 | -1.0 ± 6.24 | -0.3 ± 6.51 | 0.9 ± 9.04 |
| Day 3 (third 8 hours) | 8.8 ± 6.95 | — | — | -1.0 ± 7.55 | — | 0.2 ± 6.90 | -3.0 ± 4.58 | 0.3 ± 10.69 | 0.8 ± 6.21 |
| Day 8 | 2.4 ± 10.42 | 0.0 ± 12.77 | -6.0 ± 10.82 | -2.5 ± 5.32 | 3.7 ± 6.43 | 1.9 ± 8.52 | 3.3 ± 2.52 | -0.3 ± 8.08 | 4.2 ± 10.15 |
| Day 15 | -2.1 ± 16.71 | -1.7 ± 7.02 | 0.7 ± 7.51 | -4.7 ± 8.85 | 2.0 ± 8.89 | 3.5 ± 7.75 | 0.3 ± 3.51 | -2.3 ± 5.51 | 1.7 ± 11.81 |
| Day 22 | 0.3 ± 16.78 | -3.0 ± 9.64 | 0.7 ± 8.33 | -4.7 ± 8.80 | 5.0 ± 16.09 | 4.1 ± 9.05 | 2.0 ± 12.00 | -0.7 ± 11.55 | 1.3 ± 5.68 |
| Day 36 | -3.2 ± 14.69 | — | -5.3 ± 5.13 | -1.3 ± 9.87 | 7.0 ± 23.64 | 4.7 ± 12.38 | 6.3 ± 11.06 | -1.0 ± 10.58 | 2.6 ± 13.71 |
| Day 57 | -2.0 ± 11.87 | — | — | 2.2 ± 12.75 | 12.0 ± 18.25 | 2.9 ± 12.09 | — | 3.3 ± 7.37 | 4.1 ± 12.87 |
| Day 78 | -2.8 ± 10.13 | — | — | -1.5 ± 11.79 | 4.7 ± 16.86 | 4.3 ± 12.47 | — | 0.7 ± 11.85 | 4.3 ± 9.85 |
| Day 99 | 4.0 ± 18.38 | — | — | — | 6.7 ± 20.23 | 4.2 ± 11.40 | — | — | 7.2 ± 10.12 |
| Day 126 | 8.5 ± 17.68 | — | — | — | 13.3 ± 10.50 | 5.0 ± 15.16 | — | — | 7.3 ± 11.35 |
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) \*100. Fold Change from Baseline is the ratio of Post-Baseline to Baseline, and it is assumed to follow a lognormal distribution. Per the study design, only some participants had a Day 4/Day 5 visit. Therefore, NT-proBNP data were not collected at this time point for all participants.
| picograms per milliliter (pg/mL) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1 (2 hours post end of infusion) | 1.09 ± 26.9 | 1.26 ± 30.8 | 1.30 ± 26.9 | 0.97 ± 14.8 | 0.91 ± 11.2 | 1.01 ± 12.4 | 1.05 ± 6.6 | 1.04 ± 18.2 | 0.94 ± 13.2 |
| Day 1 (4 hours post end of infusion) | 1.13 ± 25.2 | 1.23 ± 28.4 | 1.36 ± 20.9 | 0.96 ± 12.7 | 0.95 ± 7.0 | 0.99 ± 18.3 | 0.97 ± 11.1 | 1.03 ± 19.0 | 0.89 ± 14.8 |
| Day 1 (6 hours post end of infusion) | 1.19 ± 28.7 | 1.35 ± 32.6 | 1.39 ± 20.3 | 1.01 ± 14.4 | 0.98 ± 10.0 | 1.05 ± 19.8 | 1.04 ± 12.2 | 1.19 ± 23.7 | 0.91 ± 20.8 |
| Day 2 (24 hours post end of infusion) | 1.12 ± 32.7 | 0.96 ± 18.3 | 1.12 ± 22.5 | 0.64 ± 39.2 | 1.13 ± 102.5 | 0.99 ± 23.8 | 0.79 ± 12.2 | 0.74 ± 37.7 | 0.63 ± 51.0 |
| Day 3 | 0.66 ± 25.8 | 1.00 ± 18.6 | 1.09 ± 48.2 | 0.75 ± 48.6 | 1.32 ± 126.1 | 0.77 ± 35.6 | 0.66 ± 1.7 | 0.69 ± 11.9 | 0.68 ± 32.6 |
| Day 4 | 0.98 | — | — | 0.76 ± 80.2 | — | 0.80 ± 37.2 | 0.72 ± 11.8 | 0.71 ± 15.7 | 0.89 ± 51.2 |
| Day 5 | 0.73 | — | — | 0.81 ± 49.0 | — | 0.72 ± 67.5 | 0.97 ± 13.2 | 0.89 ± 21.5 | 0.99 ± 45.6 |
| Day 8 | 1.06 ± 32.3 | 1.45 ± 36.7 | 3.01 ± 20.1 | 1.57 ± 44.7 | 1.23 ± 77.6 | 1.11 ± 38.3 | 1.02 ± 70.1 | 1.53 ± 39.8 | 1.40 ± 26.0 |
| Day 15 | 0.96 ± 51.8 | 1.41 ± 50.6 | 2.92 ± 19.0 | 1.07 ± 62.3 | 1.42 ± 28.4 | 1.18 ± 43.3 | 2.19 ± 17.2 | 1.47 ± 51.0 | 1.43 ± 50.8 |
| Day 22 | 1.00 ± 62.2 | 1.20 ± 55.0 | 1.92 ± 21.3 | 1.17 ± 56.5 | 0.80 ± 56.2 | 1.30 ± 43.5 | 1.90 ± 40.6 | 3.34 ± 150.2 | 1.29 ± 49.4 |
| Day 36 | 0.80 ± 47.3 | — | 1.41 ± 68.0 | 0.98 ± 41.5 | 0.59 ± 23.3 | 1.13 ± 38.7 | 1.41 ± 32.2 | 2.66 ± 109.5 | 1.24 ± 58.0 |
| Day 57 | 1.04 ± 93.2 | — | — | 0.76 ± 58.2 | 1.47 ± 54.3 | 1.13 ± 36.6 | — | 1.86 ± 86.3 | 1.19 ± 48.8 |
| Day 78 | 0.63 ± 56.6 | — | — | 0.79 ± 44.2 | 0.46 ± 24.4 | 1.09 ± 40.3 | — | 1.75 ± 81.5 | 0.99 ± 38.4 |
| Day 99 | 0.91 ± 37.2 | — | — | — | 0.42 ± 20.5 | 1.21 ± 42.5 | — | — | 0.90 ± 42.8 |
| Day 126 | 0.92 ± 52.2 | — | — | — | 0.63 ± 57.0 | 0.97 ± 37.7 | — | — | 1.03 ± 49.5 |
| mg/L | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|
| Peak Concentration (Cmax) of REGN5381 in Serum | 2.17 ± 0.208 | 6.38 ± 1.34 | 26.5 ± 6.06 | 61.9 ± 14.8 | 7.37 ± 1.29 | 22.7 ± 4.01 | 68.3 ± 14.1 |
| day*mg/L | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum | 5.12 ± 0.284 | 35.3 ± 7.99 | 241 ± 29.2 | 583 ± 345 | 47.2 ± 16.6 | 221 ± 38.5 | 897 ± 149 |
The ADA status of each participant was classified as one of the following: * Negative - If all samples were found to be negative in the ADA assay * Pre-existing immunoreactivity - If the baseline sample was positive and all post baseline ADA titers were reported as less than 9-fold the baseline titer value * Treatment-Boosted Response * Treatment-Emergent Response
| Participants | Groups A: Placebo | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|
| Negative | 4 | 6 | 3 | 18 | 3 | 3 | 11 |
| Pre-existing Immunoreactivity | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-Boosted Response | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-Emergent Response | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over From date of informed consent up to end of study (Day 126). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Placebo | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Group A: REGN5381 10 mg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Group A: REGN5381 30 mg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Group A: REGN5381 100 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Group A: REGN5381 300 mg | 1/4 (25%) | 2/4 (50%) | 3/4 (75%) |
| Group C: Placebo | 0/18 (0%) | 0/18 (0%) | 3/18 (16.7%) |
| Group C: REGN5381 30 mg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Group C: REGN5381 100 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Group C: REGN5381 300 mg | 0/12 (0%) | 1/12 (8.3%) | 4/12 (33.3%) |
| Event | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/7 | 0/3 | 0/3 | 0/6 | 1/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| Ischaemic hepatitisHepatobiliary disorders | 0/7 | 0/3 | 0/3 | 0/6 | 1/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| Respiratory tract procedural complicationInjury, poisoning and procedural complications | 0/7 | 0/3 | 0/3 | 0/6 | 0/4 | 0/18 | 0/3 | 0/3 | 1/12 |
| Event | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg |
|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/7 | 0/3 | 0/3 | 0/6 | 0/4 | 0/18 | 1/3 | 0/3 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/7 | 0/3 | 0/3 | 0/6 | 1/4 | 1/18 | 0/3 | 1/3 | 1/12 |
| Atrial fibrillationCardiac disorders | 0/7 | 0/3 | 0/3 | 0/6 | 0/4 | 0/18 | 0/3 | 1/3 | 0/12 |
| Catheter site discomfortGeneral disorders | 0/7 | 0/3 | 1/3 | 0/6 | 0/4 | 0/18 | 1/3 | 0/3 | 0/12 |
| Non-cardiac chest painGeneral disorders | 0/7 | 1/3 | 0/3 | 0/6 | 0/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/7 | 0/3 | 1/3 | 0/6 | 0/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| Ventricular extrasystolesCardiac disorders | 2/7 | 0/3 | 0/3 | 0/6 | 0/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| NauseaGastrointestinal disorders | 0/7 | 0/3 | 0/3 | 0/6 | 1/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| VomitingGastrointestinal disorders | 0/7 | 0/3 | 0/3 | 0/6 | 1/4 | 0/18 | 0/3 | 0/3 | 0/12 |
| COVID-19Infections and infestations | 0/7 | 0/3 | 0/3 | 0/6 | 1/4 | 0/18 | 0/3 | 0/3 | 0/12 |
Safety Analysis Set (SAF): All randomized participants who received any study drug.
| Age, Customized(Participants) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ≥ 18 to < 45 years | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| ≥ 45 to < 65 years | 5 | 3 | 3 | 3 | 4 | 7 | 0 | 2 | 5 | 32 |
| ≥ 65 to < 75 years | 2 | 0 | 0 | 1 | 0 | 11 | 3 | 1 | 6 | 24 |
| ≥ 75 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 1 | 1 | 1 | 5 | 0 | 0 | 4 | 13 |
| Male | 6 | 3 | 2 | 5 | 3 | 13 | 3 | 3 | 8 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 3 | 3 | 6 | 4 | 18 | 3 | 3 | 12 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Group A: Placebo | Group A: REGN5381 10 mg | Group A: REGN5381 30 mg | Group A: REGN5381 100 mg | Group A: REGN5381 300 mg | Group C: Placebo | Group C: REGN5381 30 mg | Group C: REGN5381 100 mg | Group C: REGN5381 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 3 | 3 | 6 | 4 | 18 | 3 | 3 | 12 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Jun 2022 to primary completion in Jun 2025, 35 months.
Results were first posted in Sep 2026, 1 year 3 months after primary completion.
Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 35 months is above that.
Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vixticibart